Singapore, June 15 -- As cell and gene therapies advance toward commercial reality, the industry's focus is rapidly shifting beyond manufacturing technologies to the operational foundations that underpin successful scale-up. In an exclusive conversation with BioSpectrum Asia, Justin Irizarry, CEO of OrganaBio, discusses the hidden complexities of donor sourcing, supply chain resilience, analytical readiness, and the evolving role of integrated CTDMOs. He shares why starting material variability remains the greatest risk to cell therapy development and how next-generation manufacturing models could reshape global access to advanced therapies.

Q1. As cell therapy pipelines continue to mature globally, where do you believe the industry stil...